Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies

Gabriel Osborn(Guy's Hospital), Sophia N. Karagiannis(King's College London), James Spicer(King's College London), Debra H. Josephs(Guy's and St Thomas' NHS Foundation Trust), James N. Arnold(Wellcome/MRC Cambridge Stem Cell Institute), Rebecca Adams(King's College London), Katie E. Lacy(King's College London), Rebecca Kristeleit(Guy's and St Thomas' NHS Foundation Trust), Ana Montes(Guy's and St Thomas' NHS Foundation Trust), Ahmad Sayasneh(Imperial College Healthcare NHS Trust), Sharmistha Ghosh(Guy's and St Thomas' NHS Foundation Trust), Chara Stavraka(King's College London)
Clinical & Experimental Immunology
November 22, 2021
10.1093/cei/uxab020
Cited by 19

Related Papers

The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution
|Cell|2020|614
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
|The Lancet Oncology|2021|614
Targeting folate receptor alpha for cancer treatment
|Oncotarget|2016|447
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
|The Lancet Oncology|2021|401
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial
|The Lancet Oncology|2019|228